Perfusion Tech ApS: Financial statements 2018
CVR: 38238213
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -261,728 and a net result of DKK -238,245 compared with DKK -271,716 the year before. Equity in the 2018 report amounted to DKK -452,673.
- Gross Profit
- DKK -261,728
- Profit/Loss
- DKK -238,245
- Equity
- DKK -452,673
- Total Assets
- DKK 470,718
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -262 t. | -238 t. | -453 t. | - |
| 2017 | - | -278 t. | -272 t. | -214 t. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Perfusion Tech ApS has published its annual report for 2017. Gross profit came to DKK -278,036, and the net result was DKK -271,716.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity in the 2025 report amounted to DKK -9,640,655.